Iovance Biotherapeutics (IOVA) Free Cash Flow (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Free Cash Flow of -$78.7 million for Q1 2026, up 28.39% year-over-year from -$61.3 million in Q1 2025, and down 27.2% quarter-over-quarter from -$61.9 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Free Cash Flow (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Free Cash Flow for 15 consecutive years, with -$78.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 28.39% year-over-year to -$78.7 million; the TTM figure through Mar 2026 stood at -$305.0 million (up 12.22% YoY), while the FY2025 annual figure was -$336.2 million, up 7.64% from the prior year.
- Free Cash Flow retreated to -$78.7 million in Q1 2026 per IOVA's latest filing, from -$61.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$61.3 million in Q3 2024 and bottomed at -$126.4 million in Q1 2024.
- Historically, Free Cash Flow has averaged -$86.8 million across 5 years, with a median of -$85.2 million in 2022.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 65.17% — and 2024, when it surged 30.12%.
- Iovance Biotherapeutics' Free Cash Flow stood at -$80.7 million in 2022, then retreated by 8.43% to -$87.5 million in 2023, then increased by 11.47% to -$77.5 million in 2024, then rose by 20.12% to -$61.9 million in 2025, then slipped by 27.2% to -$78.7 million in 2026.
- Business Quant data shows IOVA's Free Cash Flow at -$78.7 million in Q1 2026, -$61.9 million in Q4 2025, and -$89.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -66.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -66.26 Mn |
| Jun 30, 2026 | -66.26 Mn |
| Mar 31, 2026 | -78.71 Mn |
| Mar 31, 2026 | -78.71 Mn |
| Dec 31, 2025 | -61.88 Mn |
| Dec 31, 2025 | -61.88 Mn |
| Sep 30, 2025 | -89.59 Mn |
| Sep 30, 2025 | -89.59 Mn |
| Jun 30, 2025 | -74.87 Mn |
| Jun 30, 2025 | -74.87 Mn |
| Mar 31, 2025 | -109.91 Mn |
| Mar 31, 2025 | -109.91 Mn |
| Dec 31, 2024 | -77.46 Mn |
| Dec 31, 2024 | -77.46 Mn |
| Sep 30, 2024 | -61.26 Mn |
| Sep 30, 2024 | -61.26 Mn |
| Jun 30, 2024 | -98.87 Mn |
| Jun 30, 2024 | -98.87 Mn |
| Mar 31, 2024 | -126.45 Mn |
| Mar 31, 2024 | -126.45 Mn |